Valuing genetic and genomic testing in France: current challenges and latest evidence

[1]  G. Henderson,et al.  Parents’ perceptions of personal utility of exome sequencing results , 2019, Genetics in Medicine.

[2]  S. Béjean,et al.  Preference heterogeneity with respect to whole genome sequencing. A discrete choice experiment among parents of children with rare genetic diseases. , 2018, Social science & medicine.

[3]  D. Taruscio,et al.  Meeting Patients’ Right to the Correct Diagnosis: Ongoing International Initiatives on Undiagnosed Rare Diseases and Ethical and Social Issues , 2018, International journal of environmental research and public health.

[4]  Y. Lévy,et al.  Genomic medicine France 2025. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Daniele Merico,et al.  A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder , 2017, Genetics in Medicine.

[6]  P. Benusiglio.  CDH1 germline mutations: different syndromes, same management? , 2017, Genetics in Medicine.

[7]  J. Kohler,et al.  Personal utility in genomic testing: a systematic literature review , 2017, European Journal of Human Genetics.

[8]  Clara Gaff,et al.  Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement , 2017, Genetics in Medicine.

[9]  Caroline Vass,et al.  The Role of Qualitative Research Methods in Discrete Choice Experiments , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Maxwell Mehlman,et al.  Ethical, Legal, and Social Implications of Personalized Genomic Medicine Research: Current Literature and Suggestions for the Future , 2016, Bioethics.

[11]  Anke M Hövels,et al.  Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability , 2016, Genetics in Medicine.

[12]  Mauro Turrini,et al.  Beyond clinical utility: The multiple values of DTC genetics , 2016, Applied & translational genomics.

[13]  Pierre Pluye,et al.  Combining the power of stories and the power of numbers: mixed methods research and mixed studies reviews. , 2014, Annual review of public health.

[14]  S. Olson,et al.  The Economics of Genomic Medicine: Workshop Summary , 2013 .

[15]  Richard R Sharp,et al.  Evaluating the utility of personal genomic information , 2009, Genetics in Medicine.

[16]  Muin J Khoury,et al.  What is the clinical utility of genetic testing? , 2006, Genetics in Medicine.

[17]  R. Ojha,et al.  Health care policy issues as a result of the genetic revolution: implications for public health. , 2005, American journal of public health.

[18]  S. Morgan,et al.  Predictive genetic tests and health system costs. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  Franziska Wulf,et al.  Methods For The Economic Evaluation Of Health Care Programmes , 2016 .